Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

325
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
325
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

4.8K
Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
4.8K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

93
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
[3,3] Sigmatropic Rearrangement of 1,5-Dienes: Cope Rearrangement01:21

[3,3] Sigmatropic Rearrangement of 1,5-Dienes: Cope Rearrangement

2.4K
The Cope rearrangement is classified as a [3,3] sigmatropic shift in 1,5-dienes, leading to a more stable, isomeric 1,5-diene. The reaction involves a concerted movement of six electrons, four from two π bonds and two from a σ bond, via an energetically favorable chair-like transition state.
2.4K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

155
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
155

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olaparib Metabolism: Quantum Chemistry, Docking, and Dynamics-Based Insights into Mechanisms and Reactivity.

Chemical research in toxicology·2025
Same author

Sulfotransferase-mediated phase II drug metabolism prediction of substrates and sites using accessibility and reactivity-based algorithms.

Molecular informatics·2024
Same author

Mechanisms of Electron Transfer Rate Modulations in Cytochrome P450 BM3.

The journal of physical chemistry. B·2022
Same author

A property-response perspective on modern toxicity assessment and drug toxicity index (DTI).

In silico pharmacology·2021
Same author

How Do Metal Ions Modulate the Rate-Determining Electron-Transfer Step in Cytochrome P450 Reactions?

Chemistry (Weinheim an der Bergstrasse, Germany)·2020
Same author

A simple model to solve a complex drug toxicity problem.

Toxicology research·2019

Related Experiment Video

Updated: Apr 23, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

12.7K

A context-based matched molecular pair analysis identifies structural transformations that reduce CYP1A2 inhibition.

Janvi A Raut1, Vaibhav A Dixit1

  • 1Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER Guwahati), Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Govt. of India Sila Katamur (Halugurisuk), P.O.: Changsari, Dist: Kamrup 781101 Guwahati Assam India vaibhavadixit@gmail.com vaibhav@niperguwahati.in.

RSC Medicinal Chemistry
|May 29, 2025
PubMed
Summary
This summary is machine-generated.

Researchers analyzed Cytochrome P450 1A2 (CYP1A2) inhibition using matched molecular pair analysis. Context-based analysis revealed that specific structural changes, like H to Me, can reduce CYP1A2 inhibition in key drug scaffolds.

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.7K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K

Related Experiment Videos

Last Updated: Apr 23, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

12.7K
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.7K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Drug Metabolism

Background:

  • Cytochrome P450 1A2 (CYP1A2) is crucial for metabolizing approximately 10-15% of FDA-approved drugs.
  • Existing quantitative structure-activity relationship (QSAR) and machine learning models provide limited insights for designing drugs with reduced CYP1A2 inhibition.

Purpose of the Study:

  • To identify key structural transformations that reduce CYP1A2 inhibition.
  • To perform a chemical context-based analysis of CYP1A2 inhibition data.
  • To provide novel medicinal chemistry insights for lead optimization.

Main Methods:

  • Matched molecular pair analysis (MMPA) was conducted on the ChEMBL3356 CYP1A2 inhibition dataset.
  • Kramer's method was employed for a chemical context-based analysis to overcome limitations of global MMPA.
  • Structure-based analysis, including docking, was used to understand interactions with Heme-Fe.

Main Results:

  • Global MMPA findings aligned with previous QSAR studies regarding transformations like H to F, Me, OMe, and OH.
  • The impact of these transformations is highly dependent on the local chemical environment.
  • Specifically, the H to Me transformation demonstrated a reduction in inhibition across three significant pharmacological scaffolds, such as indanylpyridine.
  • Structure-based analysis revealed how transformations influence heteroatom interactions with Heme-Fe.

Conclusions:

  • This study presents the first context-based analysis of the CYP1A2 inhibition dataset.
  • The findings offer novel medicinal chemistry insights, particularly for optimizing drug leads by minimizing CYP1A2 inhibition.
  • Understanding the context-specific effects of structural modifications is vital for rational drug design.